Q4 Earnings Forecast for Genmab A/S Issued By HC Wainwright

Genmab A/S Sponsored ADR (NASDAQ:GMAB) – Research analysts at HC Wainwright upped their Q4 2025 earnings per share (EPS) estimates for shares of Genmab A/S in a report issued on Wednesday, January 28th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of $0.51 per share for the quarter, up from their previous estimate of $0.40. HC Wainwright currently has a “Buy” rating and a $39.00 price target on the stock. The consensus estimate for Genmab A/S’s current full-year earnings is $1.45 per share. HC Wainwright also issued estimates for Genmab A/S’s Q4 2026 earnings at $0.46 EPS and FY2026 earnings at $1.68 EPS.

GMAB has been the topic of a number of other research reports. Johnson Rice reissued a “buy” rating on shares of Genmab A/S in a report on Monday, October 27th. Wall Street Zen upgraded Genmab A/S from a “hold” rating to a “buy” rating in a report on Saturday, November 22nd. Weiss Ratings reissued a “hold (c)” rating on shares of Genmab A/S in a research report on Wednesday, October 8th. Truist Financial reaffirmed a “buy” rating and set a $48.00 price objective (down from $49.00) on shares of Genmab A/S in a report on Thursday, November 6th. Finally, Zacks Research downgraded shares of Genmab A/S from a “strong-buy” rating to a “hold” rating in a report on Friday, October 31st. Six investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $39.25.

Genmab A/S Price Performance

NASDAQ GMAB opened at $33.35 on Friday. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $35.43. The stock’s 50-day moving average is $32.42 and its two-hundred day moving average is $28.97. The firm has a market cap of $21.42 billion, a P/E ratio of 14.19, a price-to-earnings-growth ratio of 18.54 and a beta of 0.90.

Genmab A/S (NASDAQ:GMAB) last posted its earnings results on Thursday, November 6th. The company reported $0.65 EPS for the quarter, topping the consensus estimate of $0.48 by $0.17. The company had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $975.40 million. Genmab A/S had a net margin of 41.36% and a return on equity of 23.98%.

Hedge Funds Weigh In On Genmab A/S

Several large investors have recently bought and sold shares of GMAB. Osaic Holdings Inc. boosted its holdings in Genmab A/S by 37.8% in the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company’s stock valued at $33,000 after purchasing an additional 440 shares during the period. CWM LLC lifted its stake in shares of Genmab A/S by 50.5% in the second quarter. CWM LLC now owns 1,797 shares of the company’s stock valued at $37,000 after buying an additional 603 shares during the period. NewEdge Advisors LLC lifted its stake in shares of Genmab A/S by 1,229.0% in the third quarter. NewEdge Advisors LLC now owns 1,236 shares of the company’s stock valued at $38,000 after buying an additional 1,143 shares during the period. Brown Brothers Harriman & Co. grew its position in Genmab A/S by 143.4% during the third quarter. Brown Brothers Harriman & Co. now owns 1,324 shares of the company’s stock worth $41,000 after buying an additional 780 shares in the last quarter. Finally, Founders Capital Management increased its stake in Genmab A/S by 40.0% during the fourth quarter. Founders Capital Management now owns 1,400 shares of the company’s stock valued at $43,000 after acquiring an additional 400 shares during the period. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Key Genmab A/S News

Here are the key news stories impacting Genmab A/S this week:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $39 price target on GMAB, implying meaningful upside from current levels — a direct bullish signal from a sell?side firm. H.C. Wainwright Reiterates Buy
• Positive Sentiment: HC Wainwright raised FY2025 and Q4 2025 EPS estimates (FY2025 to $2.00; Q4 2025 to $0.51), which supports expectations for stronger near?term profitability versus prior forecasts. MarketBeat GMAB
• Neutral Sentiment: Genmab granted 32,806 restricted stock units and 34,307 warrants to employees — a routine compensation action that can modestly increase share count/dilution over time but is standard for biotech staffing and retention. Grant of Restricted Stock Units and Warrants
• Neutral Sentiment: Reported short?interest data is effectively meaningless in the latest release (shows zero/NaN), so no clear short?pressure signal is evident from the report.
• Negative Sentiment: HC Wainwright cut multiple 2026 earnings estimates: Q1 2026 to $0.27 (from $0.34), Q2 to $0.49 (from $0.58), Q3 to $0.47 (from $0.59), Q4 2026 to $0.46 (from $0.63) and FY2026 to $1.68 (from $2.14). These downward revisions indicate the analyst expects weaker 2026 earnings momentum, which could cap near?term upside despite the reiterated Buy. MarketBeat GMAB

About Genmab A/S

Genmab A/S is a Denmark-based biotechnology company specializing in the discovery and development of antibody therapeutics for the treatment of cancer. Since its founding in 1999 and with headquarters in Copenhagen, Genmab has built a robust research platform focused on harnessing novel antibody engineering technologies to create next-generation therapies. The company’s work centers on identifying targets in hematologic malignancies and solid tumors, advancing its proprietary molecules from early discovery through clinical development.

Genmab’s portfolio includes products developed in collaboration with leading global pharmaceutical partners.